1569. Package # 125 (Women's cancer panel expanded)

The expanded cancer package for women, which includes 8 markers, allows you to assess the risk of breast, ovarian, cervical, uterine, lung, colon, bladder, and thyroid cancer. It is recommended for those with a strong family history of cancer.

Package No. 125 includes an expanded panel of tumor markers covering the main cancer sites in women:

• CA 125 + HE 4 + ROMA index – assesses the risk of epithelial ovarian cancer based on menopausal status;
• CA 15-3 – a breast carcinoma marker;
• SCC (squamous cell carcinoma antigen) – indicative of cervical, laryngeal, esophageal, and lung cancer;
• Cyfra 21-1 (cytokeratin 19 fragment) – sensitive for cervical, bladder, and lung cancer;
• CEA – a nonspecific marker for the digestive organs, mammary glands, and lungs;
• calcitonin – a marker for medullary thyroid cancer.

Taken together, this package allows for the assessment of the likelihood of a wide range of oncopathologies, including occult forms.

Important to know:
Elevated tumor marker levels do not constitute a diagnosis of cancer. Results should be interpreted in conjunction with the clinical picture and other examinations (ultrasound, CT, MRI, biopsy).

Recommended: Supplement this panel with Package 129 'Cervical Screening', which includes liquid-based cytology and HPV testing – key tests for assessing the risk of cervical cancer.

• women with symptoms that may indicate cancer (weight loss, pain, abnormal discharge);
• with a family history of cancer (especially breast, ovarian, and gastrointestinal cancers);
• for follow-up after cancer treatment to detect recurrence or metastases;
• as part of an annual checkup after age 40 or as directed by a physician;
• patients with benign tumors for dynamic monitoring of the risk of malignancy.

• Venous blood

In order to exclude factors that may affect the test results, we recommend to follow the preparation rules: